Azacitidine Injection Shortage: Supply Updates and Manufacturer Availability
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Azacitidine Injection, an oncology medication, is currently experiencing supply challenges with mixed availability across several major manufacturers.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 6, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Azacitidine.
What's in Shortage
Azacitidine Injection (Brand name: AZACITIDINE) is currently listed in the FDA database as being in shortage. This medication is used in oncology and is supplied as an injection. The shortage specifically affects the 100 mg dosage forms. This shortage was initially posted on December 18, 2020, and was most recently updated on February 10, 2026.
Which Manufacturers Are Affected
Supply levels vary significantly across the five manufacturers currently listed:
- Accord Healthcare Inc.: Available. (100 mg, NDC 16729-306-10). Contact: 866-941-7875, option 2.
- Dr. Reddy's Laboratories, Inc.: Available, but limited to existing customers. (100 mg, NDC 43598-305-62). Contact: 866-732-3952.
- Fresenius Kabi USA, LLC: Available; providers are encouraged to check wholesaler inventory. (100 mg/30 mL, NDC 63323-771-39). Contact: 1-888-386-1300.
- Eugia US LLC: Currently unavailable and on backorder. Recovery date is to be determined (TBD). (100 mg/4 mL, NDC 55150-393-01). Contact: 888-238-7880.
- Teva Pharmaceuticals USA, Inc.: Currently unavailable. Estimated availability is to be determined (TBD). (100 mg, NDC 68001-313-56). Contact: 800-545-8800.
Why There's a Shortage
The FDA source data does not provide a specific reason for the current supply limitations of Azacitidine Injection.
What Patients Should Do
Patients who rely on this medication should take the following practical steps:
- Consult Your Healthcare Provider: Discuss your treatment schedule with your oncologist or doctor to ensure continuity of care.
- Speak with Your Pharmacist: Ask about current inventory levels and if they can secure supply from the manufacturers that currently have the drug available.
- Contact Manufacturers: If necessary, use the contact numbers provided above to inquire about the most recent availability updates for specific product presentations.
Disclaimer: Patients should always consult their healthcare provider regarding medical advice, dosing, and treatment alternatives.
Source
Information sourced from the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.